Global milk supply is running strong, with US output up 2.3% year over year in May and the EU posting an estimated 2.9% gain in April. That weighs on fat-focused products, but the protein complex keeps moving the other way, and the growing use of GLP-1 medication is reinforcing the divergence by shifting consumer spending toward protein.
WPC80 and whey protein isolate prices rose again on both sides of the Atlantic. Some suppliers are making product available for the first time in months, yet even that has not been enough to ease the tightness: producers continue to direct whey streams toward higher-value protein concentrates rather than dry whey, keeping supply constrained. A degree of buyer hesitancy at current levels is emerging, though it has not yet translated into downward pressure.
Sweet whey powder is behaving differently. In the EU, the pace of decline is slowing, with food-grade prices holding steady, a first constructive signal after a long slide, while US prices continued lower and the transatlantic spread stays wide. Lactose eased slightly on both sides despite structurally tight spot supply, with many US producers committed through Q3 and some into Q4.
The outlook across the complex: until protein supply meaningfully catches up, further price support is more likely than a correction in WPC80 and WPI, while sweet whey may be approaching its floor. The full analysis covers each product in detail, including permeate and MPC85.
